By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



c/o Syncona Partners LLP
215 Euston Road
London    NW1 2BE  United Kingdom
Phone: +44-0-20-7611-2031 Fax: +44-0-20-7611-2032


Company News
NightstaRx Appoints Ophthalmology Industry Veteran Scott Whitcup To Board Of Directors 5/2/2017 6:49:00 AM
NightstaRx Appoints Healthcare Finance Leader Senthil Sundaram As Chief Financial Officer 4/4/2017 3:07:56 PM
NightstaRx Commences First Phase I/II Gene Therapy Clinical Trial For Patients With X-Linked Retinitis Pigmentosa 3/20/2017 6:37:35 AM
NightstaRx Expands Leadership Team, Names Gregory Robinson, Ph.D., As Chief Scientific Officer 9/13/2016 12:24:19 PM
NightstaRx Reports Long-Term Benefits Of Gene Therapy For Inherited Form Of Progressive Blindness, As Published In The New England Journal Of Medicine 4/29/2016 1:06:52 PM
NightstaRx Announces The Start Of A Miami Gene Therapy Study To Treat Choroideremia 11/12/2015 9:55:17 AM
NightstaRx And University of Alberta Announce The Start Of The First Canadian Gene Therapy Study To Treat Choroideremia 6/29/2015 10:41:40 AM
NightstaRx Receives U.S. And European Orphan Drug Designation For Gene Therapy To Treat Choroideremia 3/11/2015 11:01:25 AM